|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 215/58 | |
| C07D 215/227 | |||
| A61K 31/47 | |||
| A61K 31/198 | |||
| A61P 37/08 |
| (11) | Number of the document | 2337779 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09812145.2 |
| Date of filing the European patent application | 2009-09-02 | |
| (97) | Date of publication of the European application | 2011-06-29 |
| (45) | Date of publication and mention of the grant of the patent | 2017-04-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2009/055692 |
| Date | 2009-09-02 |
| (87) | Number | WO 2010/028015 |
| Date | 2010-03-11 |
| (30) | Number | Date | Country code |
| 93943 P | 2008-09-03 | US |
| (72) |
GANT, Thomas G., US
SHAHBAZ, Manouchehr M., US
|
| (73) |
Teva Pharmaceutical Industries Ltd.,
5 Basel Street P.O. Box 3190, 49131 Petach-Tikva,
IL
|
| (54) | 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION |
| 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION |